A curated reference for researchers working with glucagon-like peptide compounds. Covers receptor biology, pharmacokinetics, and current preclinical applications for Semaglutide, Tirzepatide, Liraglutide, and related analogues.
All compounds listed are for research use only. Not intended for human or veterinary use.
Overview of the primary GLP receptor agonists available for preclinical research, with key pharmacological parameters and established research applications.
A long-acting GLP-1 receptor agonist structurally derived from native GLP-1 with C18 fatty acid attachment for albumin binding. Widely studied in metabolic research models for glucose regulation, appetite signaling, and weight modulation.
Research Applications
A dual GIP/GLP-1 receptor co-agonist with a novel twincretin mechanism. Research demonstrates superior metabolic outcomes compared to selective GLP-1R agonists in preclinical models, with additive effects on insulin secretion and energy expenditure.
Research Applications
An acylated GLP-1 analogue with once-daily dosing characteristics. Established preclinical model for studying GLP-1 receptor pharmacology, beta-cell preservation, and neuroprotective signaling pathways.
Research Applications
A naturally occurring GLP-1 receptor agonist isolated from Heloderma suspectum venom. Shares ~53% homology with human GLP-1 but is resistant to DPP-4 cleavage, making it a valuable research tool for long-duration GLP-1R activation studies.
Research Applications
GLP-1 receptors (GLP-1R) are class B G protein-coupled receptors expressed in pancreatic beta cells, hypothalamus, brainstem, heart, kidney, and lung. Receptor activation triggers cAMP-mediated signaling cascades that enhance glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce food intake via hypothalamic pathways. Research into GLP-1R downstream signaling (PKA, EPAC, ERK) continues to reveal novel therapeutic targets beyond metabolic disease.
Native GLP-1(7-36) amide has a plasma half-life of under 2 minutes due to rapid DPP-4 cleavage. Research analogues use structural modifications — fatty acid acylation, amino acid substitutions at position 8, and polyethylene glycol conjugation — to extend half-life from hours to days. These modifications affect receptor binding kinetics, internalization rates, and tissue distribution profiles, all of which are critical variables when designing preclinical experiments.
GLP-1 class peptides are among the most studied compounds in preclinical cardiometabolic research. Models include diet-induced obesity (DIO) in rodents, streptozotocin-induced diabetes, and high-fat diet studies. Cardiovascular endpoints — including heart rate variability, myocardial infarction recovery, and endothelial function — are increasingly common research objectives. EMPA-REG and LEADER trial data have driven academic interest in the molecular basis of GLP-1R cardioprotection.
GLP-1 receptors are expressed throughout the central nervous system, including hippocampus, substantia nigra, and cortex. Preclinical studies indicate GLP-1R agonism may attenuate neuroinflammation, reduce amyloid-beta accumulation, and support dopaminergic neuron survival. This has driven research programs examining GLP-1 analogues in Parkinson's and Alzheimer's disease models, with several investigator-initiated trials now ongoing.
Use our structured comparison tool to evaluate Semaglutide vs Tirzepatide and other GLP-class compounds across mechanism, pharmacokinetics, and research applications.
Research Use Only: All peptide compounds referenced on this page are intended solely for in vitro and in vivo laboratory research by qualified professionals. They are not approved for human or veterinary therapeutic use. US Peptide Science makes no claims regarding therapeutic efficacy. All research must comply with applicable institutional and regulatory guidelines.